EAST BRUNSWICK, N.J., Jan. 2, 2019 /PRNewswire/ -- Grace Therapeutics, a clinical stage biopharmaceutical company focused on rare and orphan diseases, announced today that it is scheduled to speak at the J.P. Morgan Healthcare Conference in San Francisco.
Grace's presentation is scheduled for Thursday, January 10, 2019 at 9.00 a.m. Pacific Time. The management team invites you to attend the session and will also be available to meet during the week.
About Grace Therapeutics
Grace Therapeutics is a rare and orphan disease drug company. Grace develops novel formulation and delivery technologies for approved molecules to address critical unmet medical needs for new and existing indications.
The company's strategy is to create differentiated products with superior value proposition, strong IP and orphan designation. The preferred regulatory pathway is 505(b)(2) which is de-risked, capital efficient, and enables expedited product approval.
Grace's pipeline consists of three distinct assets that are in advanced clinical development for Postherpetic Neuralgia, Subarachnoid Hemorrhage, and Ataxia Telangiectasia, with two additional assets for Trigeminal Neuralgia and Aortic Aneurysm that are advancing toward the clinic. Grace intends to pursue multiple commercialization options for these assets to maximize value, including establishing its own salesforce in niche markets.
The company founders have a successful track record in developing products from concept to approval and commercialization with multi-billion-dollar revenues over the product life-cycle.
To learn more, visit www.gtrx.com.
Advertisement
Grace's presentation is scheduled for Thursday, January 10, 2019 at 9.00 a.m. Pacific Time. The management team invites you to attend the session and will also be available to meet during the week.
Advertisement
About Grace Therapeutics
Grace Therapeutics is a rare and orphan disease drug company. Grace develops novel formulation and delivery technologies for approved molecules to address critical unmet medical needs for new and existing indications.
The company's strategy is to create differentiated products with superior value proposition, strong IP and orphan designation. The preferred regulatory pathway is 505(b)(2) which is de-risked, capital efficient, and enables expedited product approval.
Grace's pipeline consists of three distinct assets that are in advanced clinical development for Postherpetic Neuralgia, Subarachnoid Hemorrhage, and Ataxia Telangiectasia, with two additional assets for Trigeminal Neuralgia and Aortic Aneurysm that are advancing toward the clinic. Grace intends to pursue multiple commercialization options for these assets to maximize value, including establishing its own salesforce in niche markets.
The company founders have a successful track record in developing products from concept to approval and commercialization with multi-billion-dollar revenues over the product life-cycle.
To learn more, visit www.gtrx.com.
View original content:http://www.prnewswire.com/news-releases/grace-therapeutics-to-present-at-the-37th-annual-jp-morgan-healthcare-conference-300770971.html
SOURCE Grace Therapeutics
